) subsidiary, recently announced the addition of the new
Jenner-Wright Giemsa stain to its Dako Artisan Link
Agilent acquired the Danish cancer diagnostics company, Dako,
for $2.2 billion (on a debt-free basis) in 2012. Dako provides
antibodies, scientific instruments and software mainly to
cancer-related diagnostic labs and develops methods to identify
patients likely to benefit from certain therapies in
collaboration with drug companies.
Dako's Artisan portfolio, consisting of 31 high-quality
stains, provides the pathology labs with a broad range of
automated special stains. The portfolio enables labs to enhance
productivity through the automated Artisan Link Pro instrument.
These special stain solutions allow pathologists to make quicker
and more informed diagnoses, in turn allowing oncologists to
prescribe the relevant therapy in relatively less time.
The new stain solution, Jenner-Wright Giemsa stain, provides
clear differentiation and details of the hematopoietic cells in
bone marrow tissue samples which helps in the diagnosis of
cancer, aplastic anemia and myelofibrosis. This solution will
allow pathologist to visualize the cell morphology better.
Currently, the healthcare sector is witnessing a revolution
and special stain solutions are playing an important part in easy
and accurate diagnostics. It has been found that not all
treatments are same for cancer patients or any other patients, as
some cancer patients require solutions that are more specialized.
The whole process may revolutionize the healthcare system, as
these stain solutions may become helpful in improving patient
care and reducing medical bills.
Agilent Technologies is a broad-based original equipment
manufacturer of test and measurement equipment. In the last few
years, Agilent has been increasing focus on the life sciences,
genomics, diagnostics and wireless test markets, where it has
made a few important acquisitions. In October last year, Agilent
entered into an agreement with ABC Instrumentacion Analytica to
acquire its assets.
Agilent's revenues in the first quarter were down 2.3%
sequentially and 0.06% year over year. The major portion of
revenues came from the Asia/Pacific region, which contributed
37%, followed by the Americas with 33% and Europe, which
accounted for the balance.
However, earnings per share of 67 cents beat the Zacks
Consensus Estimate by a penny, helped by good expense control and
Agilent's shares carry a Zacks Rank #4 (Sell). Other stocks
that are performing well at current levels include
Melco Crown Entertainment Limited
Brocade Communications Systems, Inc.
). All these stocks sport a Zacks Rank #2 (Buy).
AGILENT TECH (A): Free Stock Analysis Report
AMETEK INC (AME): Free Stock Analysis Report
BROCADE COMM SY (BRCD): Free Stock Analysis
MELCO CROWN ENT (MPEL): Free Stock Analysis
To read this article on Zacks.com click here.